Thomas C. Pearce

New York
  • 1271 Avenue of the Americas
  • New York, NY 10020
  • USA

Thomas Pearce is an associate in the New York office of Latham & Watkins.

Mr. Pearce is a member of the Environment, Land & Resources Practice and Litigation & Trial Department. He represents clients in environmental, commercial, products liability, and toxic tort litigations. He also advises clients on environmental regulatory and transactional issues relating to federal environmental laws, including the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), the Clean Air Act (CAA) and the Resource Conservation and Recovery Act (RCRA), as well as their state equivalents. He has represented clients across a variety of sectors, including manufacturing, chemicals, paint and coatings, and oil and gas.

Mr. Pearce is also an active member of the firm’s pro bono program and was a recipient of the firm’s 2020 Robert M. Dell Prize for Extraordinary Pro Bono Service as part of a team that successfully litigated Voting Rights Act claims in the East Ramapo Central School District in New York.

Mr. Pearce is admitted to practice in the State of New York, the United States District Court for the Southern District of New York, and the United States District Court for the Eastern District of New York.

Mr. Pearce’s experience includes representing:

  • Multiple clients in connection with litigation and regulatory issues pertaining to per- and polyfluoroalkyl substances (PFAS)
  • Several clients in the investigation and remediation of contaminated sites under CERCLA, including the Lower Passaic River Study Area Superfund site
  • A utility in connection with the mitigation of the methane leak from the Aliso Canyon underground storage field in Porter Ranch, Los Angeles 
  • A multinational energy corporation in connection with multiple state-wide MTBE litigations
  • A property owner regarding the remediation and sale of a contaminated site subject to the New Jersey Industrial Site Recovery Act (ISRA)
  • The purchaser of a 50% equity interest in a cogeneration facility located within a complex undergoing remediation pursuant to ISRA
  • A leading US pharmaceutical company in a contractual dispute against a Swiss company relating to Medicaid reimbursement
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.